Titlebook: Research in Computational Molecular Biology; 21st Annual Interna S. Cenk Sahinalp Conference proceedings 2017 Springer International Publi

OBESE

書(shū)目名稱Research in Computational Molecular Biology影響因子(影響力)




書(shū)目名稱Research in Computational Molecular Biology影響因子(影響力)學(xué)科排名




書(shū)目名稱Research in Computational Molecular Biology網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Research in Computational Molecular Biology網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Research in Computational Molecular Biology被引頻次




書(shū)目名稱Research in Computational Molecular Biology被引頻次學(xué)科排名




書(shū)目名稱Research in Computational Molecular Biology年度引用




書(shū)目名稱Research in Computational Molecular Biology年度引用學(xué)科排名




書(shū)目名稱Research in Computational Molecular Biology讀者反饋




書(shū)目名稱Research in Computational Molecular Biology讀者反饋學(xué)科排名

Bureaucracy

Dan DeBlasio,John Kececiogluulated by certain chemical reactions that modulate parts of the genome at specific intervals involving the remodeling of chromatin. Understanding how chromatin remodeling can selectively activate or inactivate genes and subsequently influence pathogenesis and the outcome of many diseases becomes cri

sclera

Wontack Han,Mingjie Wang,Yuzhen Yees not only to enter but also infect a wide range of cells. Making use of this property, scientists have manipulated viruses to express therapeutic genes. These viruses serve as vehicles for gene delivery and are referred to as viral vectors. The ones that are currently used in gene therapy include

可能性

David Haussler,Maciej Smuga-Otto,Benedict Paten,Adam M. Novak,Sergei Nikitin,Maria Zueva,Dmitrii Miain patients with hematologic malignancies, leading to the FDA approval of five CAR-T cells for relapsed or refractory B cell malignancies. The components of these CARs (the extracellular antigen-binding domain, hinge and transmembrane region, co-stimulatory domains, and activation domain) were metho

兵團(tuán)

Guillaume Holley,Roland Wittler,Jens Stoye,Faraz Hachroaches target PD1/PDL1 pathway or use specific autologous T-cells genetically modified to express a chimeric antigen receptor (CAR). Although promising, in most patients with solid malignancies these approaches either do not work or the disease becomes resistant to treatment. Unlike CAR-T cell ther

wall-stress

Chirag Jain,Alexander Dilthey,Sergey Koren,Srinivas Aluru,Adam M. Phillippyng the treatment landscape of serious medical conditions such as autoimmune diseases, neurodegenerative disorders, and cancer. These products, including autologous or allogeneic lymphocytes, chimeric antigen receptor (CAR)-T cells, antigen-presenting cells, or cancer cells manipulated or processed e

浸軟

光亮

Uri Keich,William Stafford NobleA) approval was in 2017 for CD19-directed CAR-T cell therapy using tisagenlecleucel (tisa-cel) for the treatment of pediatric patients (up to age 25) with relapsed or refractory (R/R) B-acute lymphoblastic leukemia (B-ALL). That same year, CD19 CAR-T cell therapy with axicabtagene ciloleucel (axi-ce

Directed

改進(jìn)

Robert Osazuwa Ness,Karen Sachs,Parag Mallick,Olga Vitekenbaum oder ein Stammbaum, der unsere Beobachtungen mit den einfachsten Annahmen erkl?ren kann, ist natürlich an sich schon attraktiv. Zumindest aber sollte er ein guter Ausgangspunkt für weitere Betrachtungen sein. . wird allerdings gerade wegen seiner konzeptionellen Einfachheit von einigen moleku